Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Clinical trial NCT05394233 · UNKNOWN

Trial details

NCT number: NCT05394233
Sponsor: Sichuan Cancer Hospital and Research Institute
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-squamous Non-small Cell Lung Cancer EGFR Gene Mutation

Start date: 2022-06-01
Primary completion: 2023-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.